This session will explore the rise of state transparency laws across the country and how they are working in conjunction with government payor programs.

• Identifying states with current and pending drug pricing transparency laws under:
  • Medicaid
  • Medicare
  • PHS 340B
• Assessing state drug price transparency reporting
• Understanding how states are using the information manufacturers report
• Addressing challenges with and finding solutions for reporting under non-uniform and sometimes conflicting state laws
  • Can a state request supplemental rebates within these models?
  • If the rebate is denied, can the state exclude the drug from Medicaid coverage?